RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases.
RenBio has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in July 2024.
RenBio's investors include Wellcome Trust, DARPA, Ruentex Group.
RenBio is headquartered in New York, United States.
RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases.
RenBio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RenBio — Funding & Investors." VCBacked, July 25, 2024, https://www.vcbacked.co/company/renbio. Accessed September 30, 2026.
VCBacked. (2024). RenBio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/renbio
{{cite web |title=RenBio — Funding & Investors |url=https://www.vcbacked.co/company/renbio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated